CD8A and colorectal carcinoma: Emactuzumab (RG7155), an anti-CSF-1R antibody, has been reported to eliminate TAMs and increase T cell infiltration in a mouse model of CRC; further, its administration to humans depleted TAMs and increased the CD8/CD4 ratio [43], suggesting TAM suppression of T cell immunity.